Bone/Mineral Metabolism News

More than one-third of patients with COPD worldwide may have osteoporosis, according to a systematic review and meta-analysis published in CHEST.

Adults with chronic hypoparathyroidism treated with recombinant human parathyroid hormone 1-84 for 5 years experienced sustained improvements in mineral homeostasis and modest increases in bone turnover markers, whereas serum calcium remained in the target range with reductions in oral calcium supplements, according to findings from a small, open-label extension study.

Black adults with type 1 or type 2 diabetes do not experience additional major osteoporotic fracture risk conferred by diabetes, according to a database analysis published in The Journal of Clinical Endocrinology & Metabolism

Older men with type 2 diabetes and low baseline HbA1c were more likely to sustain any fracture or a hip fracture over 3 years than similar men with HbA1c between 7.5% and 8.5%, with insulin use further increasing fracture risk, according to findings published in the Journal of Bone and Mineral Research.

Women with severe obesity who underwent Roux-en-Y gastric bypass surgery followed by a 6-month exercise program did not experience the bone loss observed in similar women who underwent gastric bypass followed by standard care, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

A cohort of adults with obesity who underwent Roux-en-Y gastric bypass showed markers for poor bone health in the decade after surgery, including elevated bone turnover markers and lower areal bone mineral density, according to findings published in Bone.

Results from a genome-wide association study published in Nature Genetics implicated metabo-psychiatric origins of anorexia nervosa, supporting the reconceptualization of the disorder as both metabolic and psychiatric.

Each month in its cover story, Endocrine Today offers comprehensive reporting on issues of interest to practicing endocrinologists, diabetes educators and other clinicians.

More than 25% of early-middle-aged adults had osteopenia in their neck, according to findings recently published in the Journal of the American Osteopathic Association.

Long-term bisphosphonate users who switched to the human monoclonal antibody denosumab experienced a gain in hip bone mineral density in the first year of therapy, whereas patients who switched to teriparatide experienced a transient loss in hip BMD, suggesting clinicians should exercise caution when changing osteoporosis agents for patients at high risk for hip fracture, according to a real-world analysis of electronic medical records.